Abstract: The invention provides a soluble honokiol derivative (such as a water soluble honokiol derivative) and its application in antagonizing glycoprotein VI receptor and providing antioxidant and neuroprotective effects.

Abstract: A method of optimising one or more physical properties of an alloy comprises conducting a plurality of trials per an experimental design on a plurality of candidate alloys. Each trial comprises measuring a plurality of values of each physical property of the candidate alloys for different values of a plurality of parameters, wherein the parameters comprise respective concentrations of the two or more constituents, and one or more process parameters. The method further comprises fitting the plurality of values of the physical property and the plurality of parameters to a response surface model; and determining, from the fitted response surface model, optimised values of the parameters that optimise the respective responses; wherein the response surface model describes a non-linear relationship between a time integral of each of the physical property and a linear combination of non-linear functions of the plurality of parameters.

Abstract: A method of determining optimal values of one or more process parameters for printing a part comprises obtaining a plurality of sets of test values for the one or more process parameters. An additive manufacturing system is caused to at least partially generate a plurality of test samples according to a design and the plurality of sets of test values. During or after generation of the plurality of test samples, test data indicative of respective measurements of at least one property of the test samples are obtained. The test data are fitted to a second-order function of the one or more process parameters to determine coefficients of the one or more process parameters. Based on the second-order function and the coefficients, optimal values are determined for the one or more process parameters that result in a global optimum for the at least one property.

Abstract: Systems and methods for artificial intelligence enable control of hemodyamics in an individual are provided. A number of embodiments use a phenotypic response surface (PRS) that describes a physiological response to a vasopressor and/or a vasodilator to guide administration of the vasopressor and/or vasodilator. Various embodiments continually update the PRS based on changes in physiological response to the vasopressor and/or vasodilator.

Abstract: Multiple tests of a complex system are conducted by applying varying combinations of input parameters from a pool of input parameters. Results of the tests are fitted into a model of the complex system by using multi-dimensional fitting. Using the model of the complex system, identification is made of at least one optimized combination of input parameters to yield a desired response of the complex system.

Abstract: The invention provides a soluble honokiol derivative (such as a water soluble honokiol derivative) and its application in antagonizing glycoprotein VI receptor and providing antioxidant and neuroprotective effects.

Abstract: A method includes: (1) applying stimulations to a system, wherein applying the stimulations includes modulating, over time, characteristics of the stimulations; (2) measuring a time-varying response of the system to the stimulations; (3) fitting the time-varying response of the system into a model of the system; and (4) using the model of the system, identifying an optimized combination of characteristics of the stimulations to yield a desired response of the system.

Abstract: The present invention is directed to methods of treating tuberculosis by providing a pharmaceutically effective amount of a combination of drug compounds.

Abstract: A semiconductor package structure is disclosed. The package structure includes a first substrate, a second substrate on which the first substrate is disposed, and a semiconductor chip which is disposed on the first substrate. The two substrates can include two notches or two solder receiving portions. Therefore, when the package structure is disposed on the printed circuit board (PCB), the package structure will protrude less on the surface of the printed circuit board (PCB); or, the solders on the printed circuit board (PCB) will not be shifted by the package structure.

Abstract: A semiconductor package structure is disclosed. The package structure includes a first substrate, a second substrate on which the first substrate is disposed, and a semiconductor chip which is disposed on the first substrate. The two substrates can include two notches or two solder receiving portions. Therefore, when the package structure is disposed on the printed circuit board (PCB), the package structure will protrude less on the surface of the printed circuit board (PCB); or, the solders on the printed circuit board (PCB) will not be shifted by the package structure.

Abstract: Disclosed are pharmaceutical compositions and methods of treating multiple myeloma by providing a pharmaceutically effective amount of each drug in a combination of drugs.

Abstract: The invention provides a soluble honokiol detivative (such as a water soluble honokiol derivative) and its application in antagonizing glycoprotein VI receptor and providing antioxidant and neuroprotective effects.

Abstract: An initial phenotypic map is derived for a patient subjected to an initial therapeutic regimen including a first drug, based on values of a therapeutic outcome for the patient and corresponding values of a dose of the first drug administered to the patient. Following a change from the initial therapeutic regimen to an updated therapeutic regimen, an updated value of the therapeutic outcome is received for the patient subjected to the updated therapeutic regimen. The initial phenotypic map is re-calibrated according to the updated value of the therapeutic outcome, and, using the re-calibrated phenotypic map, identification is made of a value of the dose of the first drug to be administered to the patient subjected to the updated therapeutic regimen.

Abstract: The present invention is directed to methods of treating tuberculosis by providing a pharmaceutically effective amount of a combination of drug compounds.

Abstract: The present invention is directed to methods, compositions, and systems for the production of fatty acids (FAs). Specifically, the disclosed methods, compositions, and systems incorporate algal cell lysates, providing a cell-free environment that generates high levels of FAs for extended periods of time with the addition of liquid media and a carbon source.

Abstract: The present invention is directed to methods of treating tuberculosis by providing a pharmaceutically effective amount of a combination of drug compounds.

Abstract: The present invention is directed to methods of treating tuberculosis by providing a pharmaceutically effective amount of a combination of drug compounds.

Abstract: A cost function is specified to optimize a combination of N drugs, where the cost function includes at least one phenotypic contribution corresponding to efficacy and at least one phenotypic contribution corresponding to safety, and at least one of the N drugs is a nanomaterial-modified drug, with N being 2 or more. In vitro or in vivo tests are conducted by applying varying combinations of dosages of the N drugs to determine the phenotypic contributions from results of the tests. The results of the tests are fitted into a representation of the cost function, and, using the representation of the cost function, at least one optimized combination of dosages of the N drugs is identified.

Abstract: A system includes a processor and a memory storing processor-executable instructions, which when executed by the processor direct the processor to provide control data indicating application of a stimulus to a biological system, obtain sensor data indicating measurements of a response of the biological system to the stimulus, determine fitting parameters of a biological system model based on the response of the biological system to the stimulus, and predict a magnitude of the stimulus that, when applied to the biological system, will yield an optimized response of the biological system based on the model.

Abstract: A method for optimization of a response of a biological system includes: (1) obtaining measurements of a biological system in response to varying concentrations of drugs in a drug combination; (2) fitting the measurements into a model of the biological system; and (3) using the model of the biological system, predicting concentrations of the drugs in the drug combination to yield an optimized response of the biological system.